Adherent cells from adipose or placenta tissues and use thereof in therapy
AssigneePluristem Ltd.
InventorsMoran Meiron, Amir Toren, Rachel Ofir, Zami Aberman, Nirit Drori-Carmi
Life of this patent
Estimating the term…
Abstract
A method of treating ischemia in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells of a tissue selected from the group consisting of a placenta and an adipose tissue, thereby treating the ischemia in the subject. A method of treating a medical condition requiring connective tissue regeneration and/or repair is also disclosed.
Claims24
A method of treating a wound in a subject in need thereof, comprising systemically administering to the subject a therapeutically effective amount of undifferentiated placenta-derived adherent stromal cells in a liquid suspension, wherein the adherent stromal cells do not express CD34, thereby treating the wound.
A method of preparing cells for treating a wound in a subject in need thereof, the method comprising expanding placenta-derived adherent stromal cells in culture, wherein when the culture-expanded placenta-derived adherent stromal cells are subsequently systemically administered in a liquid suspension to a subject in a therapeutically effective amount they treat a wound in the subject.
A method of preparing cells for treating a wound in a subject in need thereof, the method comprising expanding non-autologous placenta-derived adherent stromal cells in three-dimensional culture, wherein when the culture-expanded placenta-derived adherent stromal cells are subsequently systemically administered in a liquid suspension to the subject in a therapeutically effective amount they treat a wound in the subject.
Dependencies are inferred from the claim text.